Kagiyama S, Tsuchihashi T, Phillips M I, Abe I, Matsumura K, Fujishima M
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
J Hypertens. 2001 Dec;19(12):2213-9. doi: 10.1097/00004872-200112000-00015.
Magnesium sulfate (MgSO4) is widely used for the treatment of eclampsia. However, effects of Mg2+ in central cardiovascular regulation remain unclear. In the present study, the role of Mg2+ on cardiovascular regulation in the rostral ventrolateral medulla (RVLM) of rats was examined.
Adult male Wistar rats were anesthetized with urethane, and artificially ventilated. The ventral surface of the medulla was exposed, and the RVLM was identified by microinjection (50 nl) of l-glutamate (l-Glu; 2 nmol). Then, MgSO4 (1, 3, 10 nmol, n = 7 for each dose) and magnesium chloride (MgCl2; 10 nmol, n = 7) were microinjected into the RVLM. l-Glu (2 nmol), N-methyl-D-aspartate (NMDA; 20 pmol), alpha-amino-3-hydroxy-5-methyl isoxazole-4-propionic acid (AMPA; 5 pmol) and (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid [(1S,3R)-ACPD, metabotropic glutamate receptor agonist; 1 nmol] were also microinjected with or without pretreatment of MgSO4 (10 nmol; n = 7 for each drug).
MgSO4 dose-dependently decreased mean arterial pressure (MAP) and heart rate (HR). The high dose of MgSO4 (10 nmol) significantly decreased MAP and HR (-25 +/- 4 mmHg and -43 +/- 6 bpm). Similarly, MgCl2 decreased MAP and HR (-27 +/- 4 mmHg and -30 +/- 6 bpm). The pressor response evoked by NMDA or (1S,3R)-ACPD was significantly attenuated by the pretreatment with MgSO4. In contrast, pressor response caused by l-Glu or AMPA was not affected by pretreatment with MgSO4.
These results suggest that Mg2+ has an inhibitory role on the RVLM neurons, and inhibits cardiovascular responses induced by NMDA and metabotropic glutamate receptor agonists.
硫酸镁(MgSO4)广泛用于子痫的治疗。然而,Mg2+在中枢心血管调节中的作用仍不清楚。在本研究中,研究了Mg2+对大鼠延髓头端腹外侧区(RVLM)心血管调节的作用。
成年雄性Wistar大鼠用乌拉坦麻醉,并进行人工通气。暴露延髓腹面,通过微量注射(50 nl)L-谷氨酸(L-Glu;2 nmol)识别RVLM。然后,将MgSO4(1、3、10 nmol,每组剂量n = 7)和氯化镁(MgCl2;10 nmol,n = 7)微量注射到RVLM中。L-Glu(2 nmol)、N-甲基-D-天冬氨酸(NMDA;20 pmol)、α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA;5 pmol)和(1S,3R)-1-氨基环戊烷-1,3-二羧酸[(1S,3R)-ACPD,代谢型谷氨酸受体激动剂;1 nmol]也在有或没有MgSO4预处理(10 nmol;每种药物n = 7)的情况下进行微量注射。
MgSO4剂量依赖性地降低平均动脉压(MAP)和心率(HR)。高剂量的MgSO4(10 nmol)显著降低MAP和HR(-25±4 mmHg和-43±6 bpm)。同样,MgCl2降低MAP和HR(-27±4 mmHg和-30±6 bpm)。MgSO4预处理显著减弱了NMDA或(1S,3R)-ACPD引起的升压反应。相比之下,L-Glu或AMPA引起的升压反应不受MgSO4预处理的影响。
这些结果表明,Mg2+对RVLM神经元具有抑制作用,并抑制NMDA和代谢型谷氨酸受体激动剂诱导的心血管反应。